The role and mechanism of pyroptosis and potential therapeutic targets in non-alcoholic fatty liver disease (NAFLD)

被引:1
作者
Li, Shu-Jing [1 ]
Liu, An-Bu [2 ]
Yu, Yuan-Yuan [2 ]
Ma, Jin-Hai [1 ]
机构
[1] Ningxia Med Univ, Gen Hosp, Dept Pediat Med, Yinchuan, Ningxia, Peoples R China
[2] Ningxia Med Univ, Gen Hosp, Dept Emergency Med, Yinchuan, Ningxia, Peoples R China
来源
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY | 2024年 / 12卷
关键词
non-alcoholic fatty liver disease (NAFLD); pyroptosis; NOD-like receptor thermal protein domain associated protein 3(NLRP3) inflammasome; gasdermin D (GSDMD); caspase; targeted therapy; NLRP3 INFLAMMASOME ACTIVATION; HEPATOCYTE PYROPTOSIS; HEPATIC STEATOSIS; CELL-DEATH; FIBROSIS; STEATOHEPATITIS; NASH; INHIBITOR; APOPTOSIS; LIPOTOXICITY;
D O I
10.3389/fcell.2024.1407738
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Non-alcoholic fatty liver disease (NAFLD) is a clinical pathological syndrome characterized by the excessive accumulation of fat within liver cells, which can progress to end-stage liver disease in severe cases, posing a threat to life. Pyroptosis is a distinct, pro-inflammatory form of cell death, differing from traditional apoptosis. In recent years, there has been growing research interest in the association between pyroptosis and NAFLD, encompassing the mechanisms and functions of pyroptosis in the progression of NAFLD, as well as potential therapeutic targets. Controlled pyroptosis can activate immune cells, eliciting host immune responses to shield the body from harm. However, undue activation of pyroptosis may worsen inflammatory responses, induce cellular or tissue damage, disrupt immune responses, and potentially impact liver function. This review elucidates the involvement of pyroptosis and key molecular players, including NOD-like receptor thermal protein domain associated protein 3(NLRP3) inflammasome, gasdermin D (GSDMD), and the caspase family, in the pathogenesis and progression of NAFLD. It emphasizes the promising prospects of targeting pyroptosis as a therapeutic approach for NAFLD and offers valuable insights into future directions in the field of NAFLD treatment.
引用
收藏
页数:14
相关论文
共 50 条
  • [21] Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH) in HIV
    Jürgen Kurt Rockstroh
    [J]. Current HIV/AIDS Reports, 2017, 14 : 47 - 53
  • [22] Non-alcoholic fatty liver disease (NAFLD) models in drug discovery
    Cole, Banumathi K.
    Feaver, Ryan E.
    Wamhoff, Brian R.
    Dash, Ajit
    [J]. EXPERT OPINION ON DRUG DISCOVERY, 2018, 13 (02) : 193 - 205
  • [23] Redox Homeostasis and Epigenetics in Non-alcoholic Fatty Liver Disease (NAFLD)
    Podrini, Christine
    Borghesan, Michela
    Greco, Azzura
    Pazienza, Valerio
    Mazzoccoli, Gianluigi
    Vinciguerra, Manlio
    [J]. CURRENT PHARMACEUTICAL DESIGN, 2013, 19 (15) : 2737 - 2746
  • [24] Epidemiology and natural history of non-alcoholic fatty liver disease (NAFLD)
    Bellentani, Stefano
    Marino, Mariano
    [J]. ANNALS OF HEPATOLOGY, 2009, 8 : S4 - S8
  • [25] Non-alcoholic fatty liver disease (NAFLD) - epidemic of the XXI century
    Maciejewska, Dominika
    Stachowska, Ewa
    [J]. POSTEPY HIGIENY I MEDYCYNY DOSWIADCZALNEJ, 2018, 72 : 659 - 670
  • [26] The New Therapeutic Approaches in the Treatment of Non-Alcoholic Fatty Liver Disease
    Filipovic, Branka
    Lukic, Snezana
    Mijac, Dragana
    Marjanovic-Haljilji, Marija
    Vojnovic, Marko
    Bogdanovic, Jelena
    Glisic, Tijana
    Filipovic, Natasa
    Al Kiswani, Jamal
    Djokovic, Aleksandra
    Kapor, Suncica
    Kapor, Slobodan
    Bukumiric, Zoran
    Starcevic, Ana
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (24)
  • [27] Exploring the link between fructose intake and Non-Alcoholic Fatty Liver Disease (NAFLD)
    Arslanbulut, Gozde
    Ciftci, Seda
    [J]. CAHIERS DE NUTRITION ET DE DIETETIQUE, 2023, 58 (06): : 399 - 409
  • [28] A Comprehensive Review on Non-Alcoholic Fatty Liver Disease
    Sahu, Prerna
    Chhabra, Pratyaksh
    Mehendale, Ashok M.
    [J]. CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (12)
  • [29] A role for IL-1 inhibitors in the treatment of non-alcoholic fatty liver disease (NAFLD)?
    Tilg, Herbert
    Effenberger, Maria
    Adolph, Timon E.
    [J]. EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2020, 29 (02) : 103 - 106
  • [30] Therapeutic Effect of Metformin on Chemerin in Non-Obese Patients with Non-Alcoholic Fatty Liver Disease (NAFLD)
    Zhuang Xianghua
    Sun Fudun
    Li Liang
    Jiang Dongqing
    Li Xiaobo
    Sun Aili
    Pan Zhe
    Lou Nengjun
    Zhang Liang
    Lou Fuchen
    [J]. CLINICAL LABORATORY, 2015, 61 (10) : 1409 - 1414